Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher T J
Life Sci. 1982 Sep 13;31(11):1133-40. doi: 10.1016/0024-3205(82)90087-x.
Stepwise modification of a conformationally stabilised analogue of the fragment of somatostatin which had been thought to be essential biologically active moiety has enabled us to synthesise the analogue H-(D) Phe-Cys-Phe-(D) Trp-Lys-Thr-Cys-Thr(ol) code-named SMS 201-995, which in vitro is three times more potent than the native hormone in inhibiting the secretion of growth hormone, which is highly resistant to degradation by pure enzymes and by tissue homogenates, which in vivo in rat and rhesus monkey is (depending on test system) at least 20 times more active than somatostatin, which is much longer acting, and which moreover in both species is much more selective in inhibiting the secretion of growth hormone than that of insulin. The compound is active by several routes of administration including the oral, is well tolerated both in laboratory animals and in man, and is currently undergoing preliminary clinical trial.
对曾被认为是生物活性必需部分的生长抑素片段的构象稳定类似物进行逐步修饰,使我们能够合成代号为SMS 201 - 995的类似物H-(D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys-Thr(ol),该类似物在体外抑制生长激素分泌的效力是天然激素的三倍,对纯酶和组织匀浆的降解具有高度抗性,在大鼠和恒河猴体内(取决于测试系统),其活性至少是生长抑素的20倍,作用时间长得多,而且在这两个物种中,它在抑制生长激素分泌方面比抑制胰岛素分泌更具选择性。该化合物通过多种给药途径(包括口服)均有活性,在实验动物和人体中耐受性良好,目前正在进行初步临床试验。